The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | Outcomes of a real-world comparison of standard-of-care ide-cel and cilta-cel in R/R myeloma
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses the outcomes from a real-world study comparing standard-of-care idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory (R/R) multiple myeloma (MM). Dr Malard highlights that cilta-cel demonstrated a higher overall response rate (ORR) compared with ide-cel, as demonstrated in previous prospective studies. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For myeloma, we have two CAR T-cells available so far, ide-cel and Cilta-cel, so the availability of the CAR T-cell will depend from one country to the other. But on the EBMT registry, we’re able to run real-world evidence data to compare these two approaches. And very similar to what we saw in the prospective study that has been conducted. We have some higher overall response rate with Cilta-cel compared to Ide-cel on a better outcome of the patient that truly confirm what we see in the study on that also confirm that why the physician when they have access to both CAR T-cells are more using now Cilta-cel versus Ide-cel for their patients...
For myeloma, we have two CAR T-cells available so far, ide-cel and Cilta-cel, so the availability of the CAR T-cell will depend from one country to the other. But on the EBMT registry, we’re able to run real-world evidence data to compare these two approaches. And very similar to what we saw in the prospective study that has been conducted. We have some higher overall response rate with Cilta-cel compared to Ide-cel on a better outcome of the patient that truly confirm what we see in the study on that also confirm that why the physician when they have access to both CAR T-cells are more using now Cilta-cel versus Ide-cel for their patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria: AstraZeneca, Bristol Myers Squibb (BMS), Jazz Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priothera, Sanofi, Therakos.
